Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Novanta’s SEC disclosures can feel like aligning a high-precision laser without a user guide. Complex revenue streams from medical insufflators, industrial photonics, and motion-control subsystems sprawl across hundreds of pages, leaving investors searching for clarity. If you’ve ever typed “Novanta SEC filings explained simply” or wondered how a sudden supply-chain disruption shows up in a “Novanta 8-K material events explained,” this page was built for you.
Stock Titan’s AI reads every line the moment it posts to EDGAR, turning dense exhibits into plain language. Need the Novanta annual report 10-K simplified? Our AI surfaces segment profitability, R&D outlays, and new laser safety standards in minutes. Curious about quarterly trends? The full Novanta quarterly earnings report 10-Q filing arrives with ratio analysis and cash-flow highlights under “Novanta earnings report filing analysis.” Real-time alerts flag each Form 4, letting you track Novanta insider trading Form 4 transactions and view a Novanta Form 4 insider transactions real-time dashboard—no manual refresh required.
Professionals rely on these insights to monitor Novanta executive stock transactions Form 4 ahead of product launches, compare laser segment margins quarter-over-quarter, and review the Novanta proxy statement executive compensation for alignment with shareholder returns. Whether you’re assessing capital-equipment demand cycles or simply understanding Novanta SEC documents with AI, our platform delivers the signals you need without the noise.
Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:
- €65.31 million 5-year Euro-denominated term loan
- $75 million 5-year US-dollar term loan
- $850 million 5-year revolving credit facility
The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0–0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00–1.75 ppt, with pricing tied to the company’s consolidated leverage ratio. A commitment fee applies to unused revolver capacity.
Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5× (step-up to 4.0× for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25×. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.
Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.
Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.
FAQ
What is the current stock price of Novanta (NOVT)?
What is the market cap of Novanta (NOVT)?
What does Novanta Inc specialize in?
What are the main business segments of Novanta Inc?
How does Novanta contribute to the medical industry?
What types of industrial applications use Novanta's technologies?
How does Novanta ensure precision and reliability in its products?
In which markets does Novanta primarily operate?
How does Novanta differentiate itself from competitors?
What should investors know about Novanta Inc's business model?
